

## Monday 25 September 2023

09:00 – 10:40	How to do and report oncological imaging?	
09:00 – 09:20	Consensus statements: how and why	K. Herrmann
09:20 – 09:40	Disease-specific structured reports and report language	A. Shinagare
09:50 – 10:10	RECIST, modified criteria and their application in various oncological settings	A. Sohaib
10:10 – 10:30	Beyond RECIST 1.1	R. Gore
11:00 – 12:40	<b>Pancreatic Cancer: The sadly rising star</b>	
11:00 – 11:20	Guidelines and structured report for pretreatment assessment	M. Wagner
11:20 – 11:40	Expert consensus for post-treatment assessment and new paradigms	M. Zins
11:50 – 12:10	Borderline resectable and locally advanced pancreatic cancer: role of FDG PET in assessing response to neoadjuvant therapy and predicting survival	J. Heiken
12:10 – 12:30	Pancreatic cystic lesions: can we make sense of the guidelines?	G. Morana (Treviso)
11:00 – 12:40	<b>Lung Cancer, Still There!</b>	
11:00 – 11:20	Lung cancer screening	R. Vliegenthart
11:20 – 11:40	Guidelines for lung nodule evaluation (Fleischner Society)	T. McCloud
11:50 – 12:10	Staging lung cancer	A. Chiti
12:10 – 12:30	Functional imaging in chest masses/lung cancer	S. Voss
13:30 – 14:00	<b>Keynote Lecture 1: Radiology at the museum: mummies, skeletons, relics and statues – Philippe Charlier</b>	
14:00 – 15:40	<b>Thyroid/NET/Adrenal: Small glands with big effects</b>	
14:00 – 14:20	Diagnostic imaging of thyroid nodules: find your pathway through the jungle of guidelines	G. Russ
14:20 – 14:40	Adrenal tumours: diagnostic work-up	K. Elsayes
14:50 – 15:10	Clinical practice guidelines for the use of minimally invasive treatments in malignant thyroid lesions	G. Russ
15:10 – 15:30	Imaging strategy of GEP-NET	W. Schima
16:00 – 17:40	<b>Colorectal Cancer: Everyone concerned</b>	
16:00 – 16:20	Pre-treatment Rectal cancer: Guidelines for imaging and reporting	K. Jhaveri
16:20 – 16:40	Neoadjuvant response of rectal cancer: Guidelines for imaging and reporting	S. Nougaret
16:50 – 17:10	Guidelines/recommendations for initial staging and follow-up of colon cancer	K. Krajewski
17:10 – 17:30	GIST, NET, Leiomyoma, when to think about	M. D'Onofrio
16:00 – 17:40	<b>Lymphoma/Myeloma: Also everyone concerned</b>	
16:00 – 16:20	Deauville criteria/ Ann Arbor/ Cheson/ Lugano staging and response assessment	S. Mulé
16:20 – 16:40	Novel PET Tracers / Imaging technique for lymphomas	M. Mayerhoefer
16:50 – 17:10	WB-MRI in myeloma and strategies to support clinical adoption	C. Messiou
17:10 – 17:30	Prognostic and predictive value of molecular imaging in haematological malignancies	W. Oyen

## Tuesday 26 September 2023

09:00 – 10:40	<b>Liver HCC/ICC: A heterogeneous disease</b>	
09:00 – 09:20	HCC diagnostic criteria: west vs east	B. Taouli
09:20 – 09:40	Not HCC but HCCs	M. Ronot
09:50 – 10:10	Which GBCA in liver diagnosis imaging? What are the recommendations?	S. Mulé
10:10 – 10:30	Intrahepatic cholangiocarcinoma: initial diagnosis and staging	B. Taouli
10:30 – 10:40	Questions & Discussion	
11:00 – 12:40	<b>The near future part 1: Theranostic &amp; new molecular probes</b>	
11:00 – 11:20	Extended field of view PET/CT	R. Hicks
11:20 – 11:40	FAP theranostics: ready for prime time?	K. Herrmann
11:50 – 12:10	PSMA theranostics: a new standard-of-care but what's next?	M. Hofman
12:10 – 12:30	Radiogenomics: The emerging and future impact on treatment selection and monitoring in prostate cancer focal therapy	F. Fennessy
12:30 – 12:40	Questions & Discussion	
11:00 – 12:40	<b>Interventional Radiology, so helpful!</b>	
11:00 – 11:20	Guidelines for treatment of HCC and upcoming improvement in interventional radiology	R. Iezzi
11:20 – 11:40	Percutaneous ablation of renal cancer: when and how?	J. Fütterer
11:50 – 12:10	Biopsy in the chest: when and how?	S. Diederich
12:10 – 12:30	Percutaneous treatment of the pain in oncology	B. Gebauer
12:30 – 12:40	Questions & Discussion	
13:30 – 14:00	<b>Keynote Lecture 2: CEST imaging – Professor Sotirios Bisdas</b>	
14:00 – 15:30	<b>My most impressive and astonishing cases, the ones I want to show to everyone!</b>	
14:30 – 14:40		A. Vargas
14:40 – 14:50		S. Voss
14:50 – 15:00		B. Taouli
15:00 – 15:10		G. Morana (Treviso)
15:10 – 15:20		E. Sala
15:20 – 15:30		P. Khong
16:00 – 17:40	<b>The female cancers</b>	
16:00 – 16:20	O-RADS US and MRI	A. Rockall
16:20 – 16:40	MRI of the breast: when?	S. Vinnicombe
16:50 – 17:10	Staging of cervical cancer: which imaging for which information? (FIGO staging and more)	R. Forstner
17:10 – 17:30	Guidelines for initial imaging of endometrium cancer	F. Fennessy
17:30 – 17:40	Questions & Discussion	
16:00 – 17:40	<b>Paediatrics: not to be neglected</b>	
16:00 – 16:20	COG/SPR whitepapers	A. Towbin
16:20 – 16:40	INSTRUCT (International Soft Tissue sarcoma ConsorTium) Imaging Guidelines for Rhabdomyosarcoma	B. McCarville
16:50 – 17:10	Functional imaging recommendations for bone and soft tissue sarcomas	S. Voss
17:10 – 17:30	A "better" understanding of embryonal CNS tumours in children	T. Huisman
17:30 – 17:40	Questions & Discussion	

## Wednesday 27 September 2023

08:30 – 10:00	<b>Along the Urinary tract : Kidney/Bladder/Prostate</b>	
08:30 – 08:46	Guidelines for prostate initial diagnosis and active surveillance (EAU clinical guidelines, PI-RADS and more)	R. Renard Penna
08:46 – 09:02	How introduction of PSMA PET/CT completely changed prostate cancer staging	W. Oyen
09:02 – 09:18	How to explore renal masses: guidelines or recommendations	A. Shinagare
09:18 – 09:34	Testicular tumour: which imaging technique for which diagnosis?	A. Sohaib
09:34 – 09:50	MRI pathway for bladder cancer and VI-RADS score: where we are and what's next	V. Panebianco
09:50 – 10:00	Questions & Discussion	
08:30 – 10:30	<b>The near future part 2: what we are going to use?</b>	
08:30 – 08:50	Imaging of the tumour microenvironment	A. Van den Abbeele
08:50 – 09:10	Current guidelines for cancer screening with WB-MRI in high-risk populations	G. Petralia
09:10 – 09:30	AI/Radiomics 2.0: How to increase translation to the clinical environment?	N. Papanikolaou
09:30 – 09:50	Recommendations for the use of radiomics and machine learning	F. Prior
09:50 – 10:00	Questions & Discussion	
10:30 – 12:00	<b>MSK &amp; Sarcoma: Not to be forgotten</b>	
10:30 – 10:50	Imaging of bone metastases:	G. Petralia
10:50 – 11:10	MET-RADS case illustrations (Response assessments of metastatic bone disease)	A. Padhani
11:10 – 11:30	Is this a lipoma or not ?	C. Messiou
11:30 – 11:50	Is this a leiomyosarcoma or not?	F. Fennessy
11:50 – 12:00	Questions & Discussion	
12:00 – 13:15	<b>Imaging of Chemotherapy/ Immunotherapy related injuries: To always keep in mind</b>	
12:00 – 12:20	Thoracic toxicities	N. Sverzellati
12:20 – 12:40	Abdominal toxicities	T. Persigehl
12:40 – 13:00	Neurological toxicities	G. Morana (Turin)
13:00 – 13:10	Questions & Discussion	
13:10 – 13:15	<b>Closing remarks</b>	<b>P. Khong</b>